Recent vaccine technology in industrial animals.
Abstract: Various new technologies have been applied for developing vaccines against various animal diseases. Virus-like particle (VLP) vaccine technology was used for manufacturing the porcine circovirus type 2 and RNA particle vaccines based on an alphavirus vector for porcine epidemic diarrhea (PED). Although VLP is classified as a killed-virus vaccine, because its structure is similar to the original virus, it can induce long-term and cell-mediated immunity. The RNA particle vaccine used a Venezuela equine encephalitis (VEE) virus gene as a vector. The VEE virus partial gene can be substituted with the PED virus spike gene. Recombinant vaccines can be produced by substitution of the target gene in the VEE vector. Both of these new vaccine technologies made it possible to control the infectious disease efficiently in a relatively short time.
Publication Date: 2016-01-27 PubMed ID: 26866019PubMed Central: PMC4742593DOI: 10.7774/cevr.2016.5.1.12Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Review
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research article provides a study on the application of new technologies in developing vaccines to treat animal diseases, with specific focus on Virus-like particle (VLP) vaccine for treating porcine circovirus type 2 and an RNA particle vaccine for controlling porcine epidemic diarrhea (PED). The new vaccines demonstrate efficient control of infectious diseases in animals in a relatively short period.
VLP Vaccine Technology
- The virus-like particle (VLP) vaccine technology involves the production of a vaccine similar in structure to the original virus, leading to induced long-term and cell-mediated immunity in the host animal. Even though VLP vaccine is considered a killed-virus vaccine, its structure similarity to the target virus makes this possible.
- Specifically, the VLP vaccine is applied to manufacture vaccines for porcine circovirus type 2. This shows the practical use of this new technology in successfully dealing with specific animal diseases.
RNA Particle Vaccine
- The research also elaborates on the RNA particle vaccine technology, which uses Venezuela equine encephalitis (VEE) virus gene as a vector. Interestingly, the VEE virus partial gene can be replaced with the PED virus spike gene.
- This technology works by substituting the target gene in the VEE vector, thereby permitting the production of recombinant vaccines. The usage of the PED virus spike gene in the manufacture of a vaccine for porcine epidemic diarrhea (PED) further underlines the practical application of this technology.
Efficient Control of Infectious Diseases
- Both the VLP and RNA particle vaccine technologies have proved efficient in controlling infectious diseases in animals. What’s particularly commendable about these new vaccines is their ability to control the diseases within a relatively short time frame.
- By concentrating on therapies for specific diseases like porcine circovirus type 2 and PED, the research showcased that industrial livestock’s health and welfare can be greatly improved with the help of these innovations in vaccine technology.
Cite This Article
APA
Kim H, Lee YK, Kang SC, Han BK, Choi KM.
(2016).
Recent vaccine technology in industrial animals.
Clin Exp Vaccine Res, 5(1), 12-18.
https://doi.org/10.7774/cevr.2016.5.1.12 Publication
Researcher Affiliations
- Optipharm, Inc., Cheongju, Korea.
- Biopharmaceutical Policy Division, Ministry of Food & Drug Safety, Cheongju, Korea.
- Optipharm, Inc., Cheongju, Korea.
- Optipharm, Inc., Cheongju, Korea.
- Optipharm, Inc., Cheongju, Korea.
Conflict of Interest Statement
No potential conflict of interest relevant to this article was reported.
References
This article includes 29 references
- Jenner E. An inquiry into the causes and effects of the variolae vaccinae. London: Dawsons of Pall Mall; 1966.
- Goldsby RA, Kindt TJ, Osborne BA. Kuby immunology. 4th ed. New York: W. H. Freeman and Company; 2000.
- Tomljenovic L, Shaw CA. Answers to common misconceptions regarding the toxicity of aluminum adjuvants in vaccines. Vaccines and autoimmunity Hoboken: John Wiley and Sons Inc.; 2015. pp. 43–56.
- Williamson D. Approaches to modelling the human immune response in transition of candidates from research to development.. J Immunol Res 2014;2014:395302.
- Berkelman RL. Human illness associated with use of veterinary vaccines.. Clin Infect Dis 2003 Aug 1;37(3):407-14.
- Harding JC. Post-weaning multisystemic wasting syndrome (PMWS): preliminary epidemiology and clinical presentation. Proc Am Assoc Swine Pract 1997;28:503.
- Ellis J, Hassard L, Clark E, Harding J, Allan G, Willson P, Strokappe J, Martin K, McNeilly F, Meehan B, Todd D, Haines D. Isolation of circovirus from lesions of pigs with postweaning multisystemic wasting syndrome.. Can Vet J 1998 Jan;39(1):44-51.
- Lyoo YS, Kim JH, Park CK. Identification of porcine circoviruses with genetic variation from lymph nodes collected in pigs with PMWS. Korean J Vet Res 1999;39:353–358.
- Meehan BM, McNeilly F, McNair I, Walker I, Ellis JA, Krakowka S, Allan GM. Isolation and characterization of porcine circovirus 2 from cases of sow abortion and porcine dermatitis and nephropathy syndrome.. Arch Virol 2001;146(4):835-42.
- Liu LJ, Suzuki T, Tsunemitsu H, Kataoka M, Ngata N, Takeda N, Wakita T, Miyamura T, Li TC. Efficient production of type 2 porcine circovirus-like particles by a recombinant baculovirus.. Arch Virol 2008;153(12):2291-5.
- Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts.. Hum Vaccin 2008 Jan-Feb;4(1):5-12.
- Chackerian B. Virus-like particles: flexible platforms for vaccine development.. Expert Rev Vaccines 2007 Jun;6(3):381-90.
- Straw BE, Zimmerman JJ, D'Allaire S, Taylor DJ. Diseases of swine. 9th ed. Ames: Blackwell Publishing; 2006.
- Buonaguro L, Tornesello ML, Buonaguro FM. Virus-like particles as particulate vaccines.. Curr HIV Res 2010 Jun;8(4):299-309.
- Schirmbeck R, Böhm W, Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen.. Intervirology 1996;39(1-2):111-9.
- Liu F, Ge S, Li L, Wu X, Liu Z, Wang Z. Virus-like particles: potential veterinary vaccine immunogens.. Res Vet Sci 2012 Oct;93(2):553-9.
- Bachmann MF, Rohrer UH, Kündig TM, Bürki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness.. Science 1993 Nov 26;262(5138):1448-51.
- Bachmann MF, Lutz MB, Layton GT, Harris SJ, Fehr T, Rescigno M, Ricciardi-Castagnoli P. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes.. Eur J Immunol 1996 Nov;26(11):2595-600.
- Mohana Subramanian B, Madhanmohan M, Sriraman R, Chandrasekhar Reddy RV, Yuvaraj S, Manikumar K, Rajalakshmi S, Nagendrakumar SB, Rana SK, Srinivasan VA. Development of foot-and-mouth disease virus (FMDV) serotype O virus-like-particles (VLPs) vaccine and evaluation of its potency.. Antiviral Res 2012 Dec;96(3):288-95.
- Porta C, Kotecha A, Burman A, Jackson T, Ren J, Loureiro S, Jones IM, Fry EE, Stuart DI, Charleston B. Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen.. PLoS Pathog 2013 Mar;9(3):e1003255.
- Stevenson GW, Hoang H, Schwartz KJ, Burrough ER, Sun D, Madson D, Cooper VL, Pillatzki A, Gauger P, Schmitt BJ, Koster LG, Killian ML, Yoon KJ. Emergence of Porcine epidemic diarrhea virus in the United States: clinical signs, lesions, and viral genomic sequences.. J Vet Diagn Invest 2013 Sep;25(5):649-54.
- Chen Q, Li G, Stasko J, Thomas JT, Stensland WR, Pillatzki AE, Gauger PC, Schwartz KJ, Madson D, Yoon KJ, Stevenson GW, Burrough ER, Harmon KM, Main RG, Zhang J. Isolation and characterization of porcine epidemic diarrhea viruses associated with the 2013 disease outbreak among swine in the United States.. J Clin Microbiol 2014 Jan;52(1):234-43.
- Morrison B, Goede D. Epidemiology an economic impact of the PED. Documento Procedente de AASV 45th Annual Meeting; 2014 Mar 1-4; Dallas, TX, USA.
- Sandbulte MR, Spickler AR, Zaabel PK, Roth JA. Optimal Use of Vaccines for Control of Influenza A Virus in Swine.. Vaccines (Basel) 2015 Jan 30;3(1):22-73.
- Strauss JH, Strauss EG. The alphaviruses: gene expression, replication, and evolution.. Microbiol Rev 1994 Sep;58(3):491-562.
- Weaver SC, Salas R, Rico-Hesse R, Ludwig GV, Oberste MS, Boshell J, Tesh RB. Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group.. Lancet 1996 Aug 17;348(9025):436-40.
- Lundstrom K. Alphavirus vectors in vaccine development. J Vaccines Vaccin 2012;3:139.
- Malone JG, Bergland PJ, Liljestrom P, Rhodes GH, Malone RW. Mucosal immune responses associated with polynucleotide vaccination.. Behring Inst Mitt 1997 Feb;(98):63-72.
- Schultz-Cherry S, Dybing JK, Davis NL, Williamson C, Suarez DL, Johnston R, Perdue ML. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses.. Virology 2000 Dec 5;278(1):55-9.
Citations
This article has been cited 8 times.- Chan OSK, Bradley KCF, Grioni A, Lau SKP, Li WT, Magouras I, Naing T, Padula A, To EMW, Tun HM, Tutt C, Woo PCY, Bloch R, Mauroo NF. Veterinary Experiences can Inform One Health Strategies for Animal Coronaviruses.. Ecohealth 2021 Sep;18(3):301-314.
- Edwards CE, Yount BL, Graham RL, Leist SR, Hou YJ, Dinnon KH 3rd, Sims AC, Swanstrom J, Gully K, Scobey TD, Cooley MR, Currie CG, Randell SH, Baric RS. Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection.. Proc Natl Acad Sci U S A 2020 Oct 27;117(43):26915-26925.
- Shepherd FK, Dvorak CMT, Murtaugh MP, Marthaler DG. Leveraging a Validated in silico Approach to Elucidate Genotype-Specific VP7 Epitopes and Antigenic Relationships of Porcine Rotavirus A.. Front Genet 2020;11:828.
- Ma J, Bruce TJ, Jones EM, Cain KD. A Review of Fish Vaccine Development Strategies: Conventional Methods and Modern Biotechnological Approaches.. Microorganisms 2019 Nov 16;7(11).
- Ma S, Wang L, Huang X, Wang X, Chen S, Shi W, Qiao X, Jiang Y, Tang L, Xu Y, Li Y. Oral recombinant Lactobacillus vaccine targeting the intestinal microfold cells and dendritic cells for delivering the core neutralizing epitope of porcine epidemic diarrhea virus.. Microb Cell Fact 2018 Feb 9;17(1):20.
- Gifre L, Arís A, Bach À, Garcia-Fruitós E. Trends in recombinant protein use in animal production.. Microb Cell Fact 2017 Mar 4;16(1):40.
- Guldner D, Hwang JK, Cardieri MC, Eren M, Ziaei P, Norton MG, Souza CD. In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A.. PLoS One 2016;11(11):e0165477.
- Langel SN, Paim FC, Lager KM, Vlasova AN, Saif LJ. Lactogenic immunity and vaccines for porcine epidemic diarrhea virus (PEDV): Historical and current concepts.. Virus Res 2016 Dec 2;226:93-107.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
